Envista Holdings Corporation (NVST) AI Stock Analysis

Envista Holdings Corporation develops, sells, and markets dental products globally across two primary segments: Specialty Products & Technologies and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery, biomaterials, and prosthetics under brands including Nobel Biocare, Alpha-Bio Tec, and Implant Direct, along with orthodontic solutions like Damon and Spark clear aligners. The Equipment & Consumables segment provides digital imaging systems, software, restorative materials, and infection prevention products under brands such as Dexis, Kerr, and Metrex, serving oral surgeons, prosthodontists, periodontists, and orthodontists.

Envista experienced revenue contraction in FY2023 and FY2024, falling 0.1% to $2.57B and 2.2% to $2.51B, alongside net losses of -$100.2M and -$1.12B, respectively. Operating margin reached -41.4% in FY2024 before rebounding to 8.3% in FY2025, when revenue grew 8.3% to $2.72B and net income recovered to $47.0M. Over the five years from FY2020 to FY2025, revenue achieved a CAGR of 7.1%. For the trailing twelve months, revenue reached $2.86B with an operating margin of 10.4% and net profit margin of 3.3%. In the latest quarter ended June 30, 2026, quarterly revenue grew 7.1% year-over-year while quarterly earnings grew 111.3%.

As of June 30, 2026, Envista held $1.13B in cash and short-term investments against total debt of $1.59B, resulting in net debt of $462.4M. Shareholders' equity was $3.08B out of $5.60B in total assets, yielding a debt-to-equity ratio of 0.52 and a current ratio of 2.43. In FY2025, the company generated $275.7M in operating cash flow and $230.4M in free cash flow, deploying $45.3M toward capital expenditures and $166.6M for share buybacks.

NVST trades at a trailing P/E of 39.5x, above the 24.6x median of its US-listed Healthcare peers, but its forward P/E of 16.8x sits below the peer median of 17.3x. The stock trades at an EV to EBITDA multiple of 10.2x compared to the peer median of 12.0x, and a price-to-sales multiple of 1.3x versus the peer median of 4.1x. Over the past year, NVST gained 16.1%, compared to a 16.8% return for the S&P 500 (SPY). Over five years, NVST returned -40.9% while the benchmark returned 83.0%.

Wall Street analysts maintain 6 Strong Buy, 2 Buy, and 7 Hold ratings on NVST, with zero Sell or Strong Sell recommendations. The mean price target of $28.69 implies an upside of 25.3% over the last close of $22.90 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $2.88B and EPS of $1.53, representing 28.6% EPS growth. Envista beat EPS expectations in each of the last 4 quarters, with its next earnings release scheduled for November 4, 2026.

This page is an AI-written research summary of Envista Holdings Corporation (NVST). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NVST income statement, NVST balance sheet, NVST key metrics, NVST analyst forecast, NVST chart. See the NVST stock overview for the latest quote and news.